The immune response to ocular herpes simplex virus type 1 infection.
Herpes simplex virus type 1 (HSV-1) is a prevalent microbial pathogen infecting 60% to 90% of the adult world population. The co-evolution of the virus with humans is due, in part, to adaptations that the virus has evolved to aid it in escaping immune surveillance, including the establishment of a latent infection in its human host. A latent infection allows the virus to remain in the host without inducing tissue pathology or eliciting an immune response. During the acute infection or reactivation of latent virus, the immune response is significant, which can ultimately result in corneal blindness or fatal sporadic encephalitis. In fact, HSV-1 is one of the leading causes of infectious corneal blindness in the world as a result of chronic episodes of viral reactivation leading to stromal keratitis and scarring. Significant inroads have been made in identifying key immune mediators that control ocular HSV-1 infection and potentially viral reactivation. Likewise, viral mechanisms associated with immune evasion have also been identified and will be discussed. Lastly, novel therapeutic strategies that are currently under development show promise and will be included in this review. Most investigators have taken full advantage of the murine host as a viable working in vivo model of HSV-1 due to the sensitivity and susceptibility to viral infection, ease of manipulation, and a multitude of developed probes to study changes at the cellular and molecular levels. Therefore, comments in this review will primarily be restricted to those observations pertaining to the mouse model and the assumption (however great) that similar events occur in the human condition.
Carr
D J
DJ
Department of Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA. dan-carr@ouhsc.edu
Härle
P
P
Gebhardt
B M
BM
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D016207:Cytokines / Q000235:genetics; D005123:Eye / Q000276:immunology; D015316:Genetic Therapy; D018259:Herpesvirus 1, Human / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007157:Immunologic Surveillance; D016849:Keratitis, Herpetic / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D012008:Recurrence
D000914:Antibodies, Viral; D016207:Cytokines